Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products

Keywords

Unresectable hepatocellular carcinoma / Combination strategies / Immunotherapy / PD-1/PD-L1 / Natural products

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 7.

[3] Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362.

[4] Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers[J]. Front Immunol, 2022, 13: 964442.

[5] Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma[J]. Hepatology, 2023, 77(5): 1773-1796.

[6] Ye ZH, Yu WB, Huang MY, et al. Building on the backbone of CD47-based therapy in cancer: combination strategies, mechanisms, and future perspectives[J]. Acta Pharm Sin B, 2023, 13(4): 1467-1487.

[7] Gao Z, Zheng S, Kamei KI, et al. Recent progress in cancer therapy based on the combination of ferroptosis with photodynamic therapy[J]. Acta Mater Med, 2022, 1(4): 411-426.

[8] Fulgenzi CAM, D'Alessio A, Airoldi C, et al. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials[J]. Eur J Cancer, 2022, 174: 57-67.

[9] Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19(3): 151-172.

[10] Huinen ZR, Huijbers EJ, van Beijnum JR, et al. Anti-angiogenic agents: overcoming tumour endothelial cell anergy and improving immunotherapy outcomes[J]. Nat Rev Clin Oncol, 2021, 18(8): 527-540.

[11] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.

[12] Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J]. NEJM Evidence, 2022, 1(8): EVIDoa2100070.

[13] Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.

[14] Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(8): 995-1008.

[15] Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146.

[16] Chen G, Zhou D, Wang CM, et al. Advances in the role of natural products in human gene expression[J]. Chin J Nat Med, 2022, 20(1): 1-8.

[17] Lu JJ, Wang YT. Identification of anti-cancer compounds from natural products[J]. Chin J Nat Med, 2020, 18(7): 481-482.

[18] Man S, Luo C, Yan M, et al. Treatment for liver cancer: from sorafenib to natural products[J]. Eur J Med Chem, 2021, 224: 113690.

[19] Li K, Xiao K, Zhu S, et al. Chinese herbal medicine for primary liver cancer therapy: perspectives and challenges[J]. Front Pharmacol, 2022, 13: 889799.

[20] Zhang J, Zhang Z, Huang Z, et al. Isotoosendanin exerts inhibition on triple-negative breast cancer through abrogating TGF-β-induced epithelial-mesenchymal transition via directly targeting TGFβR1[J]. Acta Pharm Sin B, 2023, 13(7): 2990-3007.

[21] Huang J, Liu D, Wang Y, et al. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy[J]. Gut, 2022, 71(4): 734-745.

Funding

Science and Technology Development Fund, Macau SAR(0053-2021-AGJ)

Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau(SKL-QRCM-IRG2023-011)

Natural Science Foundation of Sichuan Province(2023NSFSC1783)